A Forward Look, The Year Ahead - Research Report on The Walt Disney Company, Time Warner Inc., Hyperion Therapeutics Inc., Salix Pharmaceuticals, Ltd. and Lions Gate Entertainment Corp.
by PR Newswire
NEW YORK, March 13, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting The Walt Disney Company (NYSE:DIS), Time Warner Inc. (NYSE:TWX), Hyperion Therapeutics Inc. (NASDAQ:HPTX), Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Lions Gate Entertainment Corp. (NYSE: LGF). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
The Walt Disney Company Research Report
Disney is the owner of ABC, one of the "Big 3" US TV networks, sports-centric ESPN Television Network, and two famous amusement parks, Disney World in Florida and Disneyland in California. Its biggest cash cow, ESPN, is also the world's largest sports network. In addition, their acquisitions of Marvel and Pixar have made wonders for the company with recent box office hits like The Avengers and Toy Story 3 and will continue to do so. A more recent acquisition, Star Wars franchise owner Lucasfilm, will add on to the success as a brand new trilogy of the popular (and very profitable) franchise is set to come to your nearest theaters soon. A Motley Fool report calls Disney as "the most magical investment on Earth," with its globally recognized and loved brands, stable revenue and earnings growth, a diverse all-weather portfolio of products, proven pricing power, and relatively low debt. The Full Research Report on The Walt Disney Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/f78f_DIS]
Time Warner Inc. Research Report
Time Warner has bounced back from its failed merger with AOL with a resurgent stock price at the $100 level from its 2009 low of just a little more than $20 per share. Like Disney, the company's largest division is its TV networks business, with TBS, TNT, and premium channel HBO, and accounted for about 75 percent of Time Warner's operating profit in 2011. The company is reported to be selling its 1.1 million square-foot headquarters in New York, relinquishing the last remnant of its ill-fated AOL merger. Reuters indicate that the building could go as much as $1 billion. However, the company may still keep its portion of the Time Warner Center complex. The Full Research Report on Time Warner Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/65c0_TWX]
Hyperion Therapeutics Inc. Research Report
Hyperion isn't the first company to make a cure for the rare disease, but it is much more convenient than the existing option, Ucycld Pharma's Buphenyl. Urea cycle disorders result from a protein or enzyme deficiency in the urea cycle. Ammonia is produced during protein metabolism, and if allowed to accumulate instead of being excreted in urine, it acts as a powerful neurotoxin and the buildup can result in irreversible brain damage, coma and death. What makes the stock attractive, however, is Ravicti's potential in Hepatic Encephalopathy, a similar ailment that damages the brain when the liver can no longer remove toxic substances in the blood. This function of the drug is also under trial as of the moment, and is something for investors to watch. The Full Research Report on Hyperion Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4225_HPTX]
Salix Pharmaceuticals, Ltd. Research Report
Salix meanwhile has been upgraded by The Street to "buy" from "hold," citing robust revenue growth, good cash flow from operations, and expanding profit margins. Its latest ratings report indicates that revenues are higher by 26.6 percent, while net operating cash flow grew by 113.43 percent to $65.03 million year-on-year. Its Fulyzaq drug would most likely be just a modest contributor to Salix's pipeline, but the approval brings positivity to the company. Its approval track record over the past few quarters has not been encouraging, facing two major regulatory setbacks. The drug has an estimated 150,000 to 180,000 potential customers, i.e. people on anti-retroviral therapy suffering non-infectious diarrhea. It is also the first gastrointestinal product of its kind, with patent protection up until at least 2018. The Full Research Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/7fa0_SLXP]
Lions Gate Entertainment Corp. Research Report
Within the entertainment industry, Lions Gate Entertainment Corp. has become an analyst favorite after beating estimates in two of three quarters. Recently, Lions Gate's home entertainment release of DREDD, an adaptation of John Wagner and Carlos Ezquerra's legendary comic book, claimed the top spot on the DVD sell-through and Blu-ray charts with 650,000 units sold. The company's newest film, Warm Bodies, took $20.4 million, making it the strongest movie during the Super Bowl weekend. It will also release the second installment of the highly successful Hunger Games franchise, Catching Fire, late this year. The Full Research Report on Lions Gate Entertainment Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4fbd_LGF]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers